|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 2.600 USD | -4.41% |
|
-10.65% | -70.62% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 25.95 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -65.95% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 25.95 | 25.95 | 25.95 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -65.95% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.69x | -0.93x | 0.96x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0.1x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.22x |
| EV / Revenue | - | - | - | - | - | - | - | 0.22x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.72x | -0.68x | 0.52x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.747 | -2.783 | 2.715 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -36.12 | -38.03 | 49.46 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -35.3 | -38.03 | 49.46 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 2.600 | 2.600 | 2.600 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 2/28/22 | 3/22/23 | 4/1/24 | 3/25/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.69x | - | - | - | 25.95M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 24.02x | 26.46x | 15.68x | 0.32% | 38.31B | |
| Weighted average by Cap. | 26.72x | 25.33x | 15.90x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
